Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases

Clinical Immunology

Volumn 157, Issue 2, 2015, Pages 114-120

  Ichinose, Kunihiro ^a   Arima, Kazuhiko ^a   Ushigusa, Takeshi ^a   Nishino, Ayako ^a   Nakashima, Yoshikazu ^a   Suzuki, Takahisa ^a   Horai, Yoshiro ^a   Nakajima, Hideki ^a   Kawashiri, Shin ya ^a   Iwamoto, Naoki ^a   Tamai, Mami ^a   Nakamura, Hideki ^a   Origuchi, Tomoki ^a   Motomura, Masakatsu ^a   Kawakami, Atsushi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Cerebrospinal fluid; Cytokine profiles; Neuropsychiatric systemic lupus erythematosus; Weighted voting algorithm

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; IL15 PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; IL5 PROTEIN, HUMAN;

ALGORITHM; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; NEUROPSYCHIATRY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; ADULT; CASE CONTROL STUDY; CEREBROSPINAL FLUID; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MIDDLE AGED; NEUROMYELITIS OPTICA; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; CASE-CONTROL STUDIES; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-5; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84924225232     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.01.010     Document Type: Article

References (36)

1. Bertsias G.K., Boumpas D.T. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat. Rev. Rheumatol. 2010, 6:358-367.
2. Efthimiou P., Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod. Rheumatol. 2009, 19:457-468.
3. Fragoso-Loyo H., Richaud-Patin Y., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Llorente L., Sanchez-Guerrero J. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 2007, 56:1242-1250.
4. Hirohata S., Kanai Y., Mitsuo A., Tokano Y., Hashimoto H. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin. Rheumatol. 2009, 28:1319-1323.
5. Kira J. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology 2011, 18:69-79.
6. Uzawa A., Masahiro M., Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications. Brain Pathol. 2014, 24:67-73.
7. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., Schaller J.G., Talal N., Winchester R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25:1271-1277.
8. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42:599-608.
9. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
10. Mitchell R.M., Freeman W.M., Randazzo W.T., Stephens H.E., Beard J.L., Simmons Z., Connor J.R. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72:14-19.
11. Matsushita T., Tateishi T., Isobe N., Yonekawa T., Yamasaki R., Matsuse D., Murai H., Kira J. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013, 8:e61835.
12. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
13. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., Maeda E., Noguchi S., Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 2005, 23:422-431.
14. Hopia L., Thangarajh M., Khademi M., Laveskog A., Wallstrom E., Svenungsson E., Andersson M. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scand. J. Rheumatol. 2011, 40:363-372.
15. Fragoso-Loyo H., Atisha-Fregoso Y., Llorente L., Sanchez-Guerrero J. Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. Rheumatology 2013, 52:2218-2222.
16. Dellalibera-Joviliano R., Dos Reis M.L., Cunha Fde Q., Donadi E.A. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J. Rheumatol. 2003, 30:485-492.
17. Svenungsson E., Andersson M., Brundin L., van Vollenhoven R., Khademi M., Tarkowski A., Greitz D., Dahlstrom M., Lundberg I., Klareskog L., Olsson T. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann. Rheum. Dis. 2001, 60:372-379.
18. Lima I., Melo A., Brandi I.V., Costa O., Santiago M. Lupoid sclerosis: what is the role of antiphospholipid antibodies?. J. Clin. Rheumatol. 2007, 13:85-86.
19. Wong D., Dorovini-Zis K., Vincent S.R. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp. Neurol. 2004, 190:446-455.
20. Matsumoto T., Ikeda K., Mukaida N., Harada A., Matsumoto Y., Yamashita J., Matsushima K. Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab. Invest. 1997, 77:119-125.
21. Trysberg E., Blennow K., Zachrisson O., Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res. Ther. 2004, 6:R551-R556.
22. Dimitrijevic O.B., Stamatovic S.M., Keep R.F., Andjelkovic A.V. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 2007, 38:1345-1353.
23. Stamatovic S.M., Shakui P., Keep R.F., Moore B.B., Kunkel S.L., Van Rooijen N., Andjelkovic A.V. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J. Cereb. Blood Flow Metab. 2005, 25:593-606.
24. Crispin J.C., Tsokos G.C. IL-17 in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 2010:943254.
25. Nalbandian A., Crispin J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin. Exp. Immunol. 2009, 157:209-215.
26. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 2011, 74:1-13.
27. Humrich J.Y., Morbach H., Undeutsch R., Enghard P., Rosenberger S., Weigert O., Kloke L., Heimann J., Gaber T., Brandenburg S., Scheffold A., Huehn J., Radbruch A., Burmester G.R., Riemekasten G. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:204-209.
28. Mizui M., Koga T., Lieberman L.A., Beltran J., Yoshida N., Johnson M.C., Tisch R., Tsokos G.C. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J. Immunol. 2014, 193:2168-2177.
29. Gilad R., Lampl Y., Eshel Y., Barak V., Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br. J. Rheumatol. 1997, 36:190-193.
30. Lieberman L.A., Tsokos G.C. The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. J. Biomed. Biotechnol. 2010, 2010:740619.
31. Armitage R.J., Macduff B.M., Eisenman J., Paxton R., Grabstein K.H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 1995, 154:483-490.
32. Aringer M., Stummvoll G.H., Steiner G., Koller M., Steiner C.W., Hofler E., Hiesberger H., Smolen J.S., Graninger W.B. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 2001, 40:876-881.
33. Wen X., Zhang D., Kikuchi Y., Jiang Y., Nakamura K., Xiu Y., Tsurui H., Takahashi K., Abe M., Ohtsuji M., Nishimura H., Takatsu K., Shirai T., Hirose S. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur. J. Immunol. 2004, 34:2740-2749.
34. Carneiro J.R., Fuzii H.T., Kayser C., Alberto F.L., Soares F.A., Sato E.I., Andrade L.E. IL-2, IL-5, TNF-alpha and IFN-gamma mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions. Clinics 2011, 66:77-82.
35. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4-25.
36. Zhou L., Lu G., Shen L., Wang L., Wang M. Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance. BioMed Res. Int. 2014, 2014:627126.